Dr. Susan Scott discusses how findings from the MARIPOSA and FLAURA-2 trials will be incorporated into clinical practice. Read more
Experts Share New Insights, Key Updates During Final Plenary Session of the 2024 ACLC
Haleigh BehrmanTakeaways included updates from the CheckMate 816 study, advances in technology, the role of metabolites and mobile CT screening in predicting cancer risk, and the importance of biomarkers for guiding optimal treatment. Read more
New, Indisputable Data Demonstrate Smoking Cessation Should be Considered a First-Line Therapeutic Intervention for Thoracic Malignancies
Joelle Fathi, DNP, RN, ARNP, CTTS, FAANP, FAAN+more
Drs. Joelle Fathi and Mahdi Sheikh summarize the growing body of evidence that shows quitting smoking after diagnosis improves survival. Read more
The combination treatment is the first and only regimen to show a survival benefit that surpasses the current standard of care for EGFR-mutated lung cancer. Read more
In Brief for January 22, 2025
Haleigh BehrmanFDA issues draft guidance on the use of AI for biological and drug product submissions, China’s NMPA grants priority review for the combination of savolitinib and osimertinib, and nivolumab and hyaluronidase-nvhy receive FDA approval for subcutaneous injection. Read more
Emerging Biomarkers Have Potential to Refine Patient Selection, Improve Immunotherapy Strategies
Marina Chiara Garassino, MD+more
Drs. Marina Chiara Garassino, Sulin Wu, and Faith Abodunrin offer insights from the RELATIVITY-104 and GALAXIES Lung-201 Trials. Read more
Future Directions in Lung Cancer Treatment
Haleigh BehrmanDuring the opening plenary session at the 2024 Asia Conference on Lung Cancer, experts offered their perspectives on clinical trials, combination therapies, and research initiatives. Read more
Research to Watch: Lurbinectedin-Atezolizumab Combination Demonstrates Significant OS, PFS Benefits
Haleigh BehrmanPromising results from the phase III IMforte trial reveal a potential first-line therapy for patients with ES-SCLC. Read more
Prof. Glenwood Goss said adjuvant durvalumab did not improve disease-free survival outcomes following complete resection and optional chemotherapy. Read more
Data Shows Screening Programs Can Shift Stage Distribution at Diagnosis
Erin JungmeyerDr. Mike Gieske said since implementing a multidisciplinary screening approach, his healthcare system has seen a 19% decrease in late-stage lung cancers, and they now see more early-stage than late-stage lung cancers. Read more